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OBJECTIVE
Heterozygous loss-of-function mutations in HNF1A cause maturity-onset diabetes
of the young (MODY). Affected individuals can be treated with low-dose sulfo-
nylureas. Individuals with homozygous HNF1A mutations causing MODY have not
been reported.
RESEARCH DESIGN AND METHODS
We phenotyped a kindred with young-onset diabetes and performed molecular
genetic testing, a mixed meal tolerance test, a sulfonylurea challenge, and in vitro
assays to assess variant protein function.
RESULTS
A homozygous HNF1A variant (p.A251T) was identified in three insulin-treated
family members diagnosed with diabetes before 20 years of age. Those with the
homozygous variant had low hs-CRP levels (0.2–0.8 mg/L), and those tested dem-
onstrated sensitivity to sulfonylurea given at a low dose, completely transitioning off
insulin. In silicomodelingpredictedavariant ofunknownsignificance; however, in vitro
studies supported amodest reduction in transactivation potential (79% of that for the
wild type; P < 0.05) in the absence of endogenous HNF1A.
CONCLUSIONS
Homozygous hypomorphic HNF1A variants are a cause of HNF1A-MODY. We thus
expand the allelic spectrum of variants in dominant genes causing diabetes.
Heterozygous loss-of-function mutations in the hepatocyte nuclear factor 1-a gene
(HNF1A) causematurity-onset diabetes of the young (MODY) (1). Young age at onset,
autosomal dominant inheritance, and an excellent glycemic response to sulfonylurea
monotherapy characterize HNF1A-MODY (2). A spectrum of heterozygous HNF1A
variants have been identifieddfrom classical MODY-causing mutations that impair
insulin secretion (3,4), to milder alleles that increase the risk of type 2 diabetes.
Homozygous loss-of-function germline mutations are thought to be embryonically
lethal (5). Establishing the pathogenicity of missense variants is challenging (6,7):
hypomorphic variants in theheterozygous statemaybedismissedasbenign,butwhen
inherited recessively, they may mimic loss-of-function heterozygous mutations (8).
We describe an insulin-treated individual in whom a homozygousHNF1Amissense
variant, p.A251T (c.751G.A), was identified. We metabolically characterized both
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heterozygous carriers of the p.A251T
variant and individuals homozygous for
the p.A251T variant, performed in vitro
functional studies to test our hypothesis
that p.A251T is a hypomorphic HNF1A
mutation, and assessed the transition to
sulfonylurea therapy.
RESEARCH DESIGN AND METHODS
Intheproband,recruitedtotheMYDIABETES
(MODY in Young-Onset Diabetes in Dif-
ferent Ethnicities) study (clinical trial no.
NCT02082132, ClinicalTrials.gov), we se-
quencedHNF1Apromoters, exons, and key
flanking intronic sequences, along with 22
genes implicated in monogenic diabetes
(9), and we assessed copy number var-
iation using multiplex ligation-dependent
probe amplification (9).
In Silico Modeling of Pathogenicity
We assessed predicted pathogenicity us-
ing established in silico tools, in line with
the American College ofMedical Genetics
classification (10) and as previously de-
scribed (11). For structural analysis, we
used FoldX (12), introducing variants
p.A251T and a nearby MODY-causing
mutation, p.V246 L (13), into the struc-
ture of the HNF1A DNA binding domain
complexed with DNA (Research Collabo-
ratory for Structural Bioinformatics Pro-
tein Data Bank identifier 1IC8) (14).
Clinical Studies
We assessed clinical features and hs-CRP, a
marker of HNF1A protein function (15), in
theprobandandhisfamily.Wealsoassessed
in the proband b-cell function and glucose
response to a mixed meal tolerance test
(MMTT) (16), and his response to a 2.5-mg
glibenclamide challenge. The proband un-
derwent continuous glucose monitoring for
7-days before and after the switch to the
sulfonylurea.
In Vitro Functional Characterization
The impact of p.A251T on HNF1A function
was assessed by using a suite of in vitro
assays, as described previously (11). This
impact on function was compared with
that of wild-type HNF1A and two DNA bind-
ing domain mutations that cause MODY.
RESULTS
Clinical Characteristics of p.A251T
Variant Carriers
Young-onset diabetes cosegregated with
the homozygous, but not heterozygous,
HNF1Ap.A251T carriers; threehomozygous
individuals (proband, his identical twin,
and a sister) presented with type 1 di-
abetes as teenagers and were treated
with insulin (Supplementary Fig. 1 and
Supplementary Table 1). The father ful-
filled criteria for prediabetes and the
mother developed gestational diabetes
during her third pregnancy at age 29 years;
her diabetes persisted postpartum.
In the proband, no additional mutations
or variants were detected, and anti-GAD65
and IA2antibodieswerenegative.Although
consanguinity was not reported, both pa-
rentswere from the same region in Eastern
Europe.
Levelsofhs-CRPwerelow(#0.2–0.8mg/L)
in all those who were homozygous for
p.A251T and in the heterozygousmother
(see Supplementary Table 1). The het-
erozygous father displayed a higher
value (1.4 mg/L).
During the MMTT (see Fig. 1), blood
glucose plateaued at 12.5 mmol/L; this
was accompanied by a rise in C-peptide.
After the proband ingested glibenclamide,
C-peptide increased further, beyond the
levels measured during the MMTT. This
increase was sustained and decreased
only after glucose levels began to fall.
Glucose droppedbeyond fasting levels (to
2.9 mmol/L), however, causing hypogly-
cemia. Oral glucose was administered,
resulting in another, higher C-peptide
increase that restored normoglycemia.
The proband was discharged with a
prescription for 1.25-mg glibenclamide
once daily (which was subsequently in-
creased to twice daily); insulin was
stopped. Continuous glucose monitoring
performed before and after the treat-
ment change demonstrated the resolu-
tion of hypoglycemia andmaintenance
of glucose levels (Supplementary Fig.
2), and HbA1c was reduced to 6.9%
(52 mmol/mol). The proband’s identical
twin also transitioned from insulin to
sulfonylurea therapy.
In Silico Characterization of the
p.A251T Variant
The p.A251T variant is located in a region
of HNF1A that encodes a highly conserved
POU homeodomain DNA binding domain,
which is crucial for transcription factor
function (14). Neither p.A251T nor other
rare variants at this position were present
in the Genome Aggregation Database
(examined July 2019). A variant of un-
certain significance was predicted by
in silico approaches (see Supplementary
Table 2). Detailed structural analysis of
p.A251T compared with that of a MODY-
causing mutation (p.V246 L) at a similar
location revealed the formation of a novel
hydrogen bond (Supplementary Fig. 3).
In Vitro Functional Assessment
In vitro functional assays demonstrated a
modest reduction in transactivation activity
Figure 1—Composite graph depicting results of the MMTT and the sulfonylurea challenge in the
proband after morning premixed insulin was omitted. Glucose, C-peptide, and insulin during an
MMTT, and the glibenclamide test dose, at indicated time points are displayed. Glucogel 25 g, an
oral glucose preparation B (BI Healthcare, Bridgend, U.K.), was administered sublingually.
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andDNAbinding for p.A251T-HNF1A,which
is less severe than bona fide mutations
(p.P112L and p.R203H) that cause early-
onset diabetes (Supplementary Fig. 4).
CONCLUSIONS
We report a homozygous hypomorphic
HNF1A mutation in a family with young-
onset diabetes. The clinical phenotype is
consistent with classical heterozygous
HNF1A-MODY: individuals have low
hs-CRP and demonstrate sensitivity to
sulfonylureas, enabling a transition off
insulin. Importantly, young-onset diabe-
tes cosegregated with homozygous indi-
viduals, not heterozygous carriers. In vitro
studies support p.A251T as being a hy-
pomorphic variant with modest transac-
tivation defects only in the absence of
endogenous HNF1A. This defect is likely
driven by low DNA-binding potential.
The defects observed, however, were
less pronounced than those of reported
bona fide heterozygous MODY-causing
mutations in a similar location.
Our in silico studies provide a putative
explanation for why p.A251T could have
modest structural effects despite being
located in the POU homeodomain. We
showed that p.A251T effects are atten-
uated by the predicted formation of a
novel hydrogen bond and that structural
changes are less deleterious than those
of a similarly located MODY-causing
mutation. The hypomorphic status of
this variant is further supported by the
phenotype observed in heterozygous car-
riers, which is atypical for heterozygous
loss-of-function HNF1A mutations.
The p.A251T HNF1A variant has been
reported in two studies describing het-
erozygous carriers (17,18), bringing
the total number of reported heterozy-
gous carriers to eight. In the study by
Thanabalasinghametal. (17), theproband,
who presented with diabetes at the age
of 43 years, wasmanagedwithmetformin
and sulfonylurea therapy for 25 years.
A heterozygous relative of the proband
developed diabetes later in life, at age
80 years. Although hs-CRP levels were
low in the three carriers studied, the
level of fucosylated glycan GP30 (low
levels of which are predictive of HNF1A
mutations) was above the cutoff in two
of the three (18). In another study, a
heterozygous proband received a diag-
nosis at age 39 years and had a BMI of
27 kg/m2. The proband’s father, who
was diagnosed at age 50 years, and a
sister, diagnosed at age 53 years, had
only impaired fasting glycemia when
studied (11,18). Thus the age of hetero-
zygous carriers at diagnosis has been
markedly older (11) than that of individ-
uals who are homozygous (12, 15, and
16 years). This is consistent with incom-
plete penetrance, and reported data
suggest thatahighBMImightbe required
to unmask the effect of the variant in the
heterozygous state.
In our study, two homozygous indi-
viduals had hs-CRP levels #0.2 mg/L,
whereas the heterozygous father had a
level of 1.4 mg/Ldwithin the range ob-
served for individualswith type2diabetes
and those without diabetes (15,19). This
higher level contrasts data from previous
reports in which hs-CRP levels were
all,0.3mg/L in the heterozygous state
(17), but it could be accounted for by
his age and BMI.
The most compelling evidence favoring
pathogenicity of the biallelically inherited
p.A251T variant is the successful transition
from insulin to low-dose sulfonylurea
therapy after .10 years of diabetes. It
would not be expected that alternative
diabetes types could be effectively man-
aged with low-dose glibenclamide repli-
cating the observed responses to a
sulfonylurea in individuals with typical
heterozygous HNF1A mutations (20).
Conclusion
We conclude that biallelic hypomorphic
variants of HNF1A may present with a
typical heterozygous MODY phenotype.
Hypomorphic alleles causing MODY may
be encountered more frequently as di-
verse populations, particularly those with
autozygosity, are studied using whole-
exome or whole-genome approaches.
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